Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis

Journal of Gastroenterology

Volumn 31, Issue 5, 1996, Pages 702-709

  Berling, Rikard ^a   Ohlsson, Kjell ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute pancreatitis; Acute phase response; Aprotinin; Complement activation; CRP; IL 6; Pancreatic necrosis

Indexed keywords

ANAPHYLATOXIN; APROTININ; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; INTERLEUKIN 6; SERINE PROTEINASE INHIBITOR;

ACUTE PANCREATITIS; ACUTE PHASE RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MULTICENTER STUDY; PANCREAS NECROSIS; PERITONEUM LAVAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; APROTININ; C-REACTIVE PROTEIN; COMPLEMENT C3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MALE; MIDDLE AGED; PANCREATITIS; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

EID: 0029857048     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02347620     Document Type: Article

References (50)

1. Chiari H. Über die Selbstverdaung des menshlichen Pankreas. Z Helik 1896;17:69-96.
2. Ohlsson K. Experimental pancreatitis in the dog. Appearance of complexes between proteases and trypsin inhibitors in ascitic fluid, lymph and plasma. Scand J Gastroenterol 1971;6:642-652.
3. Geokas MC, Rinderknecht H. Free proteolytic enzymes in pancreatic juice of patients with acute pancreatitis. Am J Dig Dis 1974;19:591-598.
4. Ohlsson K, Eddeland A. Release of proteolytic enzymes in bile-induced pancreatitis in dogs. Gastroenterology 1975;69:668-675.
5. Rao KN, Tuma J, Lombardi B. Acute hemorrhagic pancreatic necrosis in mice: Intraparenchymal activation of zymogens and other enzyme changes in pancreas and serum. Gastroenterology 1976;70:720-726.
6. Borgström A, Ohlsson K. Immunoreactive trypsin in serum and peritoneal fluid in acute pancreatitis. Hoppe-Seyler's Z Physiol Chem 1978;359:677-681.
7. Yamaguchi H, Kimura T, Mimura K, Nawata H. Activation of proteases in cerulein-induced pancreatitis Pancreas 1989;4:565-571.
8. Heath DI, Cruickshank A, Gudgeon AM, et al. The relationship between pancreatic enzyme release and activation and the acute-phase protein response in patients with acute pancreatitis. Pancreas 1995;10:347-353.
9. Hirano T, Manabe T, Tobe T. Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein. J Gastroenterol Hepatol 1991;6:260-264.
10. Fric P, Slaby J, Kasafirek E, et al. Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: A novel inhibitor of pancreatic elastase. Gut 1992;33:701-706.
11. Trapnell JF, Rigby CC, Talbot CH, Duncan EHL. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177-182.
12. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-341.
13. Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: The effect of aprotinin and glucagon. Gut 1980;21:334-339.
14. Pederzoli P, Bassi C, Cavallini G, et al. The Italian multicenter trial on gabexate mesilate versus aprotinin in human acute pancreatitis (abstract from European Pancreatic Club meeting September 16-18, 1991). Digestion 1991;49(1):43.
15. Larvin M, Wilson C, Heath D, et al. Intraperitoneal aprotinin therapy and the clinical course of acute pancreatitis. Br J Surg 1992;79:456-457.
16. Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: A double-blind randomized multi-center trial. J Gastroenterol 1994;29:479-485.
17. Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operation management in acute pancreatitis. Surg Gynecol Obstet 1974;139:69-81.
18. Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems. Br J Surg 1990;77:1260-1264.
19. Tran DD, Cuesta MA. Evaluation of severity in patients with acute pancreatitis. Am J Gastroenterol 1992;87:604-608.
20. Silverstein W, Isikoff MB, Hill MC, Barkin J. Diagnostic imaging of acute pancreatitis. Am J Roentgenol 1981;137:497-502.
21. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JHC. Acute pancreatitis: Value of CT in establishing prognosis. Radiology 1990;174-331-336.
22. Warshaw A, Lee K. Serum ribonuclease elevations and pancreatic necrosis in acute pancreatitis. Surgery 1979;86:227-232.
23. 2 in human acute pancreatitis. Scand J Gastroenterol 1980;15:633-636.
24. McMahon MJ, Bowen M, Mayer AD, Cooper EH. Relationship of α-2-macroglobulin and other antiproteases to the clinical features of acute pancreatitis. Am J Surg 1984;147:164-169.
25. Lasson Å, Ohlsson K. Changes in the kallikrein kinin system during acute pancreatitis in man. Thromb Res 1984;35:27-41.
26. 1-proteinase inhibitor complexes may diagnose pancreatic abscesses early. Scand J Gastroenterol 1986;21:221-224.
27. 2 in the assessment of the severity of acute pancreatitis. Gut 1987;28:764-771.
28. Berling R, Lasson Å, Axelsson L, et al. Plasma CRP levels in the prediction of complications during acute pancreatitis. Surg Res Comm 1990;8:241-249.
29. Windsor JA, Fearon KCH, Ross JA, et al. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. Br J Surg 1993;80:1042-1046.
30. Roxvall L, Bengtsson A, Heideman M. Anaphylatoxin generation in acute pancreatitis. J Surg Res 1989;47:138-143.
31. Schapira M, de Agostini A, Schifferli JA, Colman RW. Biochemistry and pathophysiology of human C1 inhibitor: Current issues. Complement 1985;2:111-126.
32. Prograis LJ, Brickman CM, Frank MM. C1 inhibitor (C1-INH). J Med 1985;16:303-350.
33. Mayer AD, McMahon MJ, Bowen M, Cooper EH. C-reactive protein: An aid to assessment and monitoring of acute pancreatitis. J Clin Pathol 1984;37:207-211.
34. Büchler M, Malfertheimer P, Schoetensack C, et al. Sensitivity of antiproteases, complement factors and C-reactive protein in detecting pancreatic necrosis. Results of a prospective clinical study. Int J Pancreatol 1986;1:227-235.
35. Wilson C, Heads A, Shenkin A, Imrie CW. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 1987;76:177-181.
36. Castell JV, Gómez-Lechón MJ, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-350
37. Morrone G, Ciliberto G, Oliviero S, et al. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 1988;263:12554-12558.
38. Leser H-G, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782-785.
39. Viedma JA, Pérez-Mateo M, Domínguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A Gut 1992;33:1264-1267.
40. Heath DI, Cruickshank A, Gudgeon M, et al. Role of interleukin-6 in mediating the acute phase response and potential as an early means of severity assessment in acute pancreatitis. Gut 1993;34:41-45.
41. Laurell C-B. Electroimmunoassay. Scand J Clin Lab Invest 1972;29(Suppl 124):21-37.
42. Gallimore MJ, Friberg P. Simple chromogenic peptide substrat assays for determing prekallikrein, kinin and kallikrein "like" activity in human plasma. Thromb Res 1982;25:293-298.
43. Boyden A, Button E, Germerog D. Precipitin testing with special reference to the measurement of turbidity. J Immunol 1947;57:211.
44. Hack CE, Ogilvie AC, Eisele B, et al. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994;388:335-357.
45. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393-402.
46. Vesentini S, Benetti L, Bassi C, et al. Effects of choline-esterase inhibitor in experimental acute pancreatitis in rats. Int J Pancreatol 1993;13:217-220.
47. Cicardi M, Testoni P, Bergamaschini L, et al. Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med Int 1994;9:180-182.
48. Larvin M, Chalmers AG, McMahon MJ. Dynamic contrast-enhanced CT: Precise identification and localisation of pancreatic necrosis complicating acute pancreatitis. Br Med J 1990;330:1425-1428.
49. McMahon MJ Plasma markers of pancreatic necrosis. In: Bradley III EL (ed). Acute pancreatitis: Diagnosis and therapy. New York: Raven 1994;47-55.
50. Ueyama M, Maruyama I, Osame M, Sawada Y. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med 1992;120:693-698.